Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 3/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015130 | 1.00 | POLG (0.41) | POLGTK1DNMT1ADRB1P2RY1 | |
| SCHEMBL19884492 | 0.92 | P2RY1 (0.42) | POLGTK1P2RY1 | |
| SCHEMBL26757510 | 0.91 | POLG (0.40) | POLGTK1P2RY1POLB | |
| SCHEMBL26757229 | 0.91 | POLG (0.40) | POLGTK1P2RY1POLB | |
| SCHEMBL22292287 | 0.89 | TK1 (0.38) | POLGTK1DNMT1ADRB1P2RY1 | |
| SCHEMBL12087575 | 0.89 | DNMT1 (0.36) | POLGTK1DNMT1ADRB1 | |
| SCHEMBL12015123 | 0.89 | DNMT1 (0.36) | POLGTK1DNMT1ADRB1 | |
| SCHEMBL23102039 | 0.88 | POLG (0.38) | POLGTK1DNMT1ADRB1P2RY1 | |
| SCHEMBL67563 | 0.86 | ALB (0.38) | POLGTK1DNMT1ADRB1DNMT3B | |
| SCHEMBL12087580 | 0.86 | ALB (0.38) | POLGTK1DNMT1ADRB1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| EP-2305805-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | POLG 90/4885TK1 563/4885DNMT1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.